Get the Stockscreener App
7.97
3.39%
-0.28
Maplight Therapeutics Inc stock is traded at $7.97, with a volume of 305.64K.
It is down -3.39% in the last 24 hours and down -23.80% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$8.25
Open:
$8.18
24h Volume:
305.64K
Relative Volume:
0.79
Market Cap:
$442.94M
Revenue:
Net Income/Loss:
$-161.15M
P/E Ratio:
-2.1454
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-0.38%
1M Performance:
-23.80%
6M Performance:
-73.22%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$7.84
$8.58
52-Week Range:
$7.46
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
7.97 | 442.94M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-26 | Initiated | Guggenheim | Neutral |
| Aug-10-26 | Downgrade | UBS | Buy → Neutral |
| Jul-28-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-21-26 | Initiated | BMO Capital Markets | Outperform |
| Jun-25-26 | Initiated | Raymond James | Strong Buy |
| May-27-26 | Initiated | UBS | Buy |
| May-21-26 | Initiated | Craig Hallum | Buy |
| May-04-26 | Initiated | H.C. Wainwright | Buy |
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
MapLight Therapeutics’ Kreitzer sells $96,024 in common stock By Investing.com - Investing.com South Africa
MapLight Therapeutics CMO Erin Foff sells $124,068 in stock By Investing.com - Investing.com South Africa
Form 4 MapLight Therapeutics Inc: James Woodruff Lillie (Chief Scientific Officer) For: 15 October - Investing.com Nigeria
MapLight Therapeutics CMO Erin Foff sells $124,068 in stock - Investing.com
MapLight Therapeutics chief scientific officer sells $93,025 in shares - Investing.com
MapLight Therapeutics general counsel reports $72,881 stock sale - Investing.com
MapLight Therapeutics CAO sells $82,149 in shares - Investing.com
MapLight Therapeutics’ Kreitzer sells $96,024 in common stock - Investing.com
MapLight Therapeutics CAO sells $82,149 in shares By Investing.com - Investing.com UK
MapLight Therapeutics chief scientific officer sells $93,025 in shares By Investing.com - Investing.com UK
Form 4 MapLight Therapeutics Inc: Anatol Kreitzer (Chief Discovery Officer) For: 15 October - Investing.com Nigeria
Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com Nigeria
Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com India
Form 144 MapLight Therapeutics For: 16 October By Investing.com - Investing.com UK
MapLight Therapeutics Officer Christopher Kroeger Files to Sell 73,691 Shares to Cover RSU Tax Withholding - Kalkine Media
MapLight Therapeutics Officer Lillie James Woodruff to Sell 11,513 Shares for RSU Tax Withholding - Kalkine Media
MapLight Therapeutics Director Robert Malenka Announces Sale of 14,809 RSU Shares via Rule 144 - Kalkine Media
Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 MapLight Therapeutics Inc For: 26 September By Investing.com - Investing.com Australia
MapLight Therapeutics (MPLT) exec to sell shares under preset trading plan - stocktitan.net
MapLight Therapeutics, Inc. (MPLT) Stock Price Quote Today & Current Price Chart - Capital.com
MapLight Therapeutics to Participate in Upcoming Investor Conference - The Manila Times
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 5.3%Here's What Happened - MarketBeat
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com Canada
Needham cuts MapLight Therapeutics price target on dilution concerns By Investing.com - Investing.com India
Maplight Therapeutics (NASDAQ:MPLT) Price Target Lowered to $43.00 at Needham & Company LLC - MarketBeat
Freestone Grove Partners LP Makes New $6.05 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Nan Fung Group Holdings Ltd Makes New $34.81 Million Investment in Maplight Therapeutics, Inc. $MPLT - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 4.6%What's Next? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 7.8% HigherShould You Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - stocktitan.net
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight Therapeutics (MPLT) grants CSO new options and RSUs - stocktitan.net
MapLight Therapeutics (MPLT) lifts GC stake with 31K options - stocktitan.net
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Morgan Stanley Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $21 - Moomoo
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - Moomoo
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foff Erin Pennock | Chief Medical Officer |
Oct 15 '26 |
Sale |
8.08 |
15,355 |
124,068 |
296,906 |
| Kroeger Christopher A. | Chief Executive Officer |
Oct 15 '26 |
Sale |
8.08 |
73,691 |
595,423 |
1,195,909 |
| Lillie James Woodruff | Chief Scientific Officer |
Oct 15 '26 |
Sale |
8.08 |
11,513 |
93,025 |
198,597 |
| Lillie James Woodruff | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
11,513 |
89,917 |
0 |
| Kroeger Christopher A. | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
73,691 |
575,527 |
0 |
| GILLIS JONATHAN | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
10,167 |
79,404 |
0 |
| Hanson Kristopher | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
9,020 |
70,446 |
0 |
| Foff Erin Pennock | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
15,355 |
119,922 |
0 |
| GILLIS JONATHAN | CAO and Interim CFO |
Oct 15 '26 |
Sale |
8.08 |
10,167 |
82,149 |
142,315 |
| Anatol Kreitzer | Officer |
Oct 15 '26 |
Proposed Sale |
7.81 |
12,500 |
97,625 |
0 |
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):